Cambrian BioPharma Inc's Form 4 filing
Faeth Therapeutics, Inc. (FTH) · filed Mar 1, 2022
- Accession no.
- 0001567619-22-005913
- Filed
- Mar 1, 2022
- Trade date
- Feb 28-Mar 1, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $9.00K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cambrian BioPharma IncCIK 0001797409 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2022 | Common Stock | PPurchaseAcquired | +42 | $3.60 | +$151.2 | 5,228,328 | Direct | |
| Mar 1, 2022 | Common Stock | PPurchaseAcquired | +2,458 | $3.60 | +$8,848.8 | 5,230,786 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.